The objectives of the Cancer Research Informatics Core (CRIC) are: 1. To maintain a cost-effective, user friendly and efficient cancer research informatics core resource for Cancer Center investigators. This Core oversees the computing resources needed for handling on-line clinical data entry, data from basic science experiments, and the data management and analytical requirements for epidemiological investigations, population survey and translational research. The main focus is on the design and development of research databases for the data acquisition needed for these research investigations. 2. To coordinate with the Biostatistics Core, the Translational Pathology Core, the Molecular Genomics Core and the Clinical Investigations Support Office (CISO) all research data management and applications for Cancer Center investigators. In this capacity, this Core provides user training in the use of the various databases and assists in software development, deployment, and maintenance. In addition, members of this Core consult on the acquisition of new computing equipment and software to insure its compatibility with existing hardware and software systems that are utilized for research activities. 3. To oversee and assist in the Center's caBIG deployment and adoption activities. 4. To coordinate with Cancer Center administration any data management needs for the research management and administrative needs of the Center. These activities are not funded by the CCSG.

Public Health Relevance

Access to and use of electronic information has become essential to most facets of cancer research. As our Cancer Center expands its translational research activities, there is a growing need for information systems that can capture and analyze data from all of the various research activities at the Center. Investigators in all of areas of the Center (population, clinical and basic sciences) are utilizing the expertise of the CRIC to accomplish their research goals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401
Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13
Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62
Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6
Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37
Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77
Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002
Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89
Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18

Showing the most recent 10 out of 345 publications